Skip to main content

Intellia Therapeutics, Inc. (NTLA) Stock Analysis

SellVALUE-TRAP 2/5High Confidence

Healthcare · Biotechnology

Sell if holding. Engine safety override at $12.35: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 3.6/10 and A.R:R 6.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 39%; Elevated put/call ratio: 12.32; Below-average business quality.

Intellia Therapeutics is a clinical-stage biopharma developing CRISPR gene editing therapies. Lead programs: lonvo-z (Phase 3 HAELO trial for hereditary angioedema, topline data expected mid-2026, BLA planned H2 2026) and nex-z (Phase 3 for ATTR amyloidosis; MAGNITUDE on FDA... Read more

$12.35+95.6% A.UpsideScore 3.6/10#155 of 157 Biotechnology
QualityF-score3 / 9FCF yield-14.10%
Stop $11.41Target $23.98(analyst − 10%)A.R:R 6.4:1
Analyst target$26.65+115.8%20 analysts
$23.98our TP
$12.35price
$26.65mean
$95

Sell if holding. Engine safety override at $12.35: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 3.6/10 and A.R:R 6.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 39%; Elevated put/call ratio: 12.32; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 3.6/10, high confidence.

Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 78d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.

Val5.4Qual1.8Grw0.1Mom3.4Sent7.6Ins5.0Peer1.6Tech5.9Risk2.53.6OVERALL

Recent Developments — Intellia Therapeutics, Inc.

Latest news

Generated 2026-05-20T21:56:22Z.

Thesis

Rewards
No bull case signals
Risks
Quality below floor (1.8 < 4.0)
Value-trap signals (2/5): Margin compression (op margin -12.4%), Material insider selling (114 sells, 0.20% of cap)

Key Metrics

P/E (TTM)—
P/E (Fwd)-6.2
Mkt Cap$1.7B
EV/EBITDA-3.3
Profit Mgn0.0%
ROE-56.3%
Rev Growth-9.5%
Beta1.93
DividendNone
Rating analysts30

Quality Signals

Piotroski F3/9

Options Flow

P/C12.32bearish
IV85%elevated
Max Pain$3-75.7% vs spot

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

5 floor-breakers

Revenue shrinking — -9.5% YoY. Growth thesis broken unless recovery story develops.static

Revenue Growth
0.1
Declining revenue: -10%
Low model confidence on this dimension (33%).

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Quality Rank
1.9
Value Rank
2.0
Growth Rank
2.6

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Roe
0.0
Roa
0.0
Gross Margin
0.0
Net Margin
0.0
Fcf Quality
0.0
Piotroski F
3.3
Moat
4.0
Current Ratio
6.9
Cash-burning: FCF -356% of revenueNo competitive moatWeak Piotroski F-Score: 3/9Quality concerns

Volatile — 8.3% daily ATR makes tight stops impractical. Position-size conservatively.static

Short Interest
0.0
Volatility
0.0
Put Call
0.0
Implied Vol
0.0
Max Pain Risk
3.0
Days To Cover
3.6
Beta
3.6
Debt Equity
9.5
High short interest justified: 39%Elevated put/call: 12.32High IV: 85%Above max pain $3

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Macd
0.0
Volume
0.1
Ma Position
2.2
Rsi
4.5
Obv
10.0
Volume accumulation (rising OBV)Below 200-MA but MA still rising (+2.8%/30d) — pullback in uptrend, not confirmed weakness
GatesMomentum 3.4<4.5A.R:R 6.4 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 78d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Aggressive
RSI
42 · Neutral
↓ 20D MA↓ 50D MA↓ 200D MAGOLDEN CROSSSupport $11.76Resistance $16.97

Price Targets

$11
$24
A.Upside+94.2%
A.R:R6.4:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Quality below floor (1.8 < 4.0)
! Value-trap signals (2/5): Margin compression (op margin -12.4%), Material insider selling (114 sells, 0.20% of cap)
! Momentum score 3.4/10 — below 4.5 minimum

Earnings

B
B
B
B
4/4 beats
Next Earnings2026-08-06 (78d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is NTLA stock a buy right now?

Sell if holding. Engine safety override at $12.35: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 3.6/10 and A.R:R 6.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 39%; Elevated put/call ratio: 12.32; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $11.41. Score 3.6/10, high confidence.

What is the NTLA stock price target?

Take-profit target: $23.98 (+95.6% upside). Prior stop was $11.41. Stop-loss: $11.41.

What are the risks of investing in NTLA?

Quality below floor (1.8 < 4.0); Value-trap signals (2/5): Margin compression (op margin -12.4%), Material insider selling (114 sells, 0.20% of cap).

Is NTLA overvalued or undervalued?

Intellia Therapeutics, Inc. trades at a P/E of N/A (forward -6.2). TrendMatrix value score: 5.4/10. Verdict: Sell.

What do analysts say about NTLA?

30 analysts cover NTLA with a consensus score of 3.7/5. Average price target: $27.

What does Intellia Therapeutics, Inc. do?Intellia Therapeutics is a clinical-stage biopharma developing CRISPR gene editing therapies. Lead programs: lonvo-z...

Intellia Therapeutics is a clinical-stage biopharma developing CRISPR gene editing therapies. Lead programs: lonvo-z (Phase 3 HAELO trial for hereditary angioedema, topline data expected mid-2026, BLA planned H2 2026) and nex-z (Phase 3 for ATTR amyloidosis; MAGNITUDE on FDA clinical hold since Oct 2025, MAGNITUDE-2 hold lifted Jan 2026). Regeneron shares ~25% of worldwide ATTR development costs and profits.

Related stocks: AUPH (Aurinia Pharmaceuticals Inc) · HALO (Halozyme Therapeutics, Inc.) · HRMY (Harmony Biosciences Holdings, I) · GLPG (Galapagos NV) · ADMA (ADMA Biologics Inc)